• 1
    Goldman S, Copeland J, Moritz T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation. 1989;80(5):11901197.
  • 2
    Lawrie GM, Lie JT, Morris GC Jr, et al. Vein graft patency and intimal proliferation after aortocoronary bypass: early and long-term angiopathologic correlations. Am J Cardiol. 1976;38(7):856862.
  • 3
    Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation. 1991;83(5):15261533.
  • 4
    Angelini GD. Saphenous vein graft failure: etiologic considerations and strategies for prevention. Curr Opin Cardiol. 1992;7(6):939944.
  • 5
    Batayias GE, Barboriak JJ, Korns ME, et al. The spectrum of pathologic changes in aortocoronary saphenous vein grafts. Circulation. 1977;56(3 suppl):II18II22.
  • 6
    Paz MA, Lupon J, Bosch X, et al. Predictors of early saphenous vein aortocoronary bypass graft occlusion. The GESIC Study Group. Ann Thorac Surg. 1993;56(5):11011106.
  • 7
    Moor E, Blomback M, Silveira A, et al. Haemostatic function in patients undergoing coronary artery bypass grafting: peroperative perturbations and relations to saphenous vein graft closure. Thromb Res. 2000;98(1):3949.
  • 8
    Rifon J, Paramo JA, Panizo C, et al. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorto-coronary bypass surgery. Br J Haematol. 1997;99(2):262267.
  • 9
    Dotani MI, Elnicki DM, Jain AC, et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol. 2000;86(10):11281130, A6.
  • 10
    Zampoulakis JD, Kyriakousi AA, Poralis KA, et al. Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes. Clin Cardiol. 2000;23(12):895900.
  • 11
    Agewall S, Fagerberg B. Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men. Clin Cardiol. 2002;25(6):287290.
  • 12
    Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9(5):579592.
  • 13
    Hoff HF, Beck GJ, Skibinski CI, et al. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation. 1988;77:12381244.
  • 14
    Burke AP, Fonseca V, Kolodgie F, et al. Increased serum homocysteine and sudden death resulting from coronary atherosclerosis with fibrous plaques. Arterioscler Thromb Vasc Biol. 2002;22:19361941.
  • 15
    Klerk M, Verhoef P, Clarke R, et al; MTHFR Studies Collaboration Group. MTHFR 677C. T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:20232031.
  • 16
    Nurk E, Tell GS, Vollset SE, et al. Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. Arch Intern Med. 2002;162(12):13741381.
  • 17
    Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281(19):18171821.
  • 18
    Ariyo A, Hennekens CH, Stampfer MJ, et al. Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physician's Health Study. J Cardiovasc Risk. 1998;5(4):273278.
  • 19
    Eritsland J, Arnesen H, Seljeflot I, et al. Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting. Am J Cardiol. 1994;74(11):10991102.
  • 20
    Iwama Y, Mokuno H, Yokoi H, et al. Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery. J Cardiol. 1998;32(6):357362.
  • 21
    Iwama Y, Mokuno H, Watanabe Y, et al. Relationship between plasma homocysteine levels and saphenous vein graft disease after coronary artery bypass grafts. Jpn Heart J. 2001;42(5):553562.
  • 22
    Harris M, Shammas NW, Jerin M. Elevated levels of low-density lipoprotein cholesterol, homocysteine, and lipoprotein(a) are associated with the occurrence of symptomatic bypass graft disease 1 year following coronary artery bypass graft surgery. Prev Cardiol. 2004;7:106108.
  • 23
    Maron BA, Loscalzo J. Should hyperhomocysteinemia be treated in patients with atherosclerotic disease? Curr Atheroscler Rep. 2007;9:375383.
  • 24
    Ridker PM, Rifai N, Pfeffer MA, et al; Cholesterol And Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839844.
  • 25
    Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:15671577.
  • 26
    Bønaa KH, Njølstad I, Ueland PM, et al; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:15781588.
  • 27
    Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565575.